11 episodes

The Endpoints Podcast features guests from the ALS community, including people living with ALS, researchers, advocates and fundraisers. Each episode cuts to the chase with short, digestible conversations about the latest research at ALS TDI and the most closely watched ALS clinical trials as well as stories from people living with ALS with their thoughts on research, healthcare and their journey with ALS.

The Endpoints Podcast is hosted by the ALS Therapy Development Institute (ALS TDI) the world's foremost drug discovery lab focused solely on ALS. ALS TDI is a non-profit biotech with one mission. End ALS.

To access all episodes of the Endpoints Podcast, visit als.net/endpoints.

Endpoints ALS TDI

    • Science
    • 5.0, 8 Ratings

The Endpoints Podcast features guests from the ALS community, including people living with ALS, researchers, advocates and fundraisers. Each episode cuts to the chase with short, digestible conversations about the latest research at ALS TDI and the most closely watched ALS clinical trials as well as stories from people living with ALS with their thoughts on research, healthcare and their journey with ALS.

The Endpoints Podcast is hosted by the ALS Therapy Development Institute (ALS TDI) the world's foremost drug discovery lab focused solely on ALS. ALS TDI is a non-profit biotech with one mission. End ALS.

To access all episodes of the Endpoints Podcast, visit als.net/endpoints.

    Day by Day: The Reich Family Fights ALS

    Day by Day: The Reich Family Fights ALS

    When Corey Reich was diagnosed with ALS in 2007, at the age of 21, his family – his sister Clare, and their parents Ted and Wendy – knew they would do whatever they could to support him. Soon after, they discovered ALS TDI and decided that they would dedicated themselves to helping to further our mission to find effective treatments for the disease – as fundraisers, spokespeople, and even as employees.

    Today, we’re joined by the Reichs, who share their story of working to end ALS – together as a family.

    Support the show.

    • 25 min
    The Lloyd Brothers: Racing for ALS

    The Lloyd Brothers: Racing for ALS

    Today we’re joined by David and Scott Lloyd, the brothers behind Racing for ALS. Growing up, David and Scott shared a love of fast cars, but as they got older, began careers, and had families, they kept putting off their dreams of auto racing. That all changed in 2017, when David was diagnosed with ALS.

    Realizing there was no better time than the present, David and Scott bought themselves a pair of high-performance cars and began organizing racing events to benefit ALS research. To learn more about Racing for ALS you can find them on: Facebook: https://fundraise.als.net/davesrace 

    Instagram: https://www.instagram.com/racingforals/.

    If you’re interested in participating in Dave’s Race 2020, visit https://fundraise.als.net/davesrace

    To access all episodes of the Endpoints Podcast, visit https://www.als.net/endpoints/.

    The Endpoints Podcast is produced by the ALS Therapy Development Institute.

    Support the show.

    • 19 min
    What to Know About CMAP

    What to Know About CMAP

     In this episode of the Endpoints Podcast, Dr. Theo Hatzipetros, the Director of Pharmacology at the ALS Therapy Development Institute (ALS TDI) joins us to discuss CMAP and the role it now plays at the lab. CMAP, which stands for Compound Muscle Action Potentials, is a technique used by neurologists to diagnose neuromuscular diseases and monitor disease progression. In mouse models of ALS used at the ALS TDI lab, CMAP can be used to detect and track disease progression before signs would be noticeable by Neuroscore, the traditional way of monitoring disease progression that relies on the human eye to detect it. Detecting signs of ALS earlier allows researchers to determine the efficacy of potential drugs quicker and ensures that the best drug candidates are advanced to the next stage for further testing.

    Support the show.

    • 16 min
    What to know about AMX0035

    What to know about AMX0035

    In this episode of the Endpoints, Dr. Steve Perrin, CSO at the ALS Therapy Development Institute, sits down to talk about AMX0035, a drug consisting of a combination of two small molecule compounds: sodium phenylbutyrate and tauroursodeoxycholic acid (TUDCA). Amylyx, the sponsor of AMX0035, recently completed enrollment of a 132 participant phase 2 trial. To learn more about the ALS Therapy Development Institute and our mission to end ALS, click here.

    • 8 min
    Collin Hadley: Choosing to use Mechanical Ventilation for ALS

    Collin Hadley: Choosing to use Mechanical Ventilation for ALS

    In this episode of the Endpoints, Collin Hadley joins Gabrielle Bellitti, Outreach and Engagement Specialist at ALS TDI, to talk about living with ALS and using mechanical ventilation.

    • 21 min
    Samantha Van Saun: Building an ALS Community

    Samantha Van Saun: Building an ALS Community

    In this episode of the Endpoints Podcast, Dileep Dadlani, Development Director at ALS TDI is joined by Samantha Van Saun who is a Champion in ALS TDI’s ALS Community in Richmond, VA. Samantha has lost her father, uncle and sister to an aggressive form of ALS but is determined to fight back by raising awareness and funds for ALS research. Listen in to find out more about her families journey with ALS.

    • 6 min

Customer Reviews

5.0 out of 5
8 Ratings

8 Ratings

@kaceasquith ,

Learned a lot!

Great podcast! Very informative as well as interesting!! I highly recommend. It also led me to their website which had even more information. Very happy to listen!!!

EDhon ,

Helpful

Very informative!

Top Podcasts In Science

Listeners Also Subscribed To